Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence.
GLP-1激動劑和SGLT2抑制劑在懷孕和哺乳期間對後代結果的影響:證據的系統性回顧。
Front Endocrinol (Lausanne) 2023-10-27
Case Series: Exposure to Glucagon-like Peptide-1 Receptor Agonist in the First Trimester of Pregnancy in Two Siblings.
病例系列:兩個同胞在懷孕第一季度暴露於類胰高血糖素-1受體激動劑。
Endocr Metab Immune Disord Drug Targets 2023-11-08
Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy.
GLP-1 受體激動劑及其他第二線抗糖尿病藥物在早期懷孕中的安全性。
JAMA Intern Med 2024-02-06
A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists.
使用胰高血糖素樣肽-1受體激動劑的安全性和有效性評論與荟萃分析。
Medicina (Kaunas) 2024-03-30
Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services.
GLP1受體激動劑在早期懷孕中的使用及生殖安全性:基於六個胎兒學資訊服務數據庫的多中心、觀察性、前瞻性cohort研究。
BMJ Open 2024-04-27
A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment.
與 GLP-1 受體激動劑在 2 型糖尿病及肥胖治療中相關的嚴重不良事件回顧。
Pharmacol Rep 2024-08-02
Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks.
針對肥胖的胰高血糖素樣受體-1激動劑:體重減輕結果、耐受性、副作用及風險。
Obes Pillars 2024-09-17